Finance

Beta
Lists
RLAY:NASDAQ
Relay Therapeutics Inc
$19.74
+6.36%
(+1.18) 1D
$19.80
+0.30% (+0.060)
After hours
Closed: Jun 29, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLAY...
Open
$18.53
High
$19.93
Low
$18.48
Mkt. cap
4.26B
Avg. vol.
5.19M
Volume
4.21M
52-wk high
$19.93
52-wk low
$3.02
EPS
-$1.57
Beta
1.75
Shares outstanding
217.94M
No. of employees
193
Open
$18.53
High
$19.93
Low
$18.48
Mkt. cap
4.26B
Avg. vol.
5.19M
Volume
4.21M
52-wk high
$19.93
52-wk low
$3.02
EPS
-$1.57
Beta
1.75
Shares outstanding
217.94M
No. of employees
193
News stories
From sources across the web
About Relay Therapeutics Inc
CEO-
Employees193
Founded2015
Headquarters-
SectorBiotechnology
Websiterelaytx.com
Analyst ratings
Based on 10 analysts giving stock ratings to RLAY in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for RLAY in the last 3 months.
Highest
Current $19.74
$28.00 (+41.84%)
Average
$23.56 (+19.35%)
Lowest
$20.00 (+1.32%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yaron Werber
TD Cowen
Buy
Reiterated
-
-
06/18/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$22.00
+11.4%
06/02/2026
Chi Meng Fong
Bank of America Securities
Buy
Maintained
$21.00
+6.4%
06/02/2026
Boris Peaker
JonesTrading
Buy
Reiterated
$20.00
+1.3%
06/02/2026
Bradley Canino
Guggenheim
Buy
Maintained
$26.00
+31.7%
05/25/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$28.00
+41.8%
05/26/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
$21.00
+6.4%
05/20/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
$21.00
+6.4%
05/19/2026
Etzer Darout
Barclays
Buy
Maintained
$27.00
+36.8%
05/20/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$26.00
+31.7%
05/19/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$18.00
-8.8%
05/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$22.00
+11.4%
05/06/2026
Danya Ben-Hail
JonesTrading
Hold
Initiated
$18.00
-8.8%
04/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
677.00K
-
7.00M
3.00M
Cost of goods sold
61.47M
67.89M
56.34M
70.56M
Cost of revenue
61.47M
67.89M
56.34M
70.56M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.75M
12.50M
13.59M
11.03M
Operating expense
13.75M
12.50M
13.59M
11.03M
Total operating expenses
75.22M
80.39M
69.93M
81.59M
Operating income
-74.55M
-80.39M
-62.93M
-78.59M
Other non operating income
-633.00K
-165.00K
30.00K
-53.00K
EBT including unusual items
-70.38M
-74.15M
-54.89M
-73.29M
EBT excluding unusual items
-68.08M
-74.15M
-57.19M
-73.29M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-70.38M
-74.15M
-54.89M
-73.29M
Net profit margin
-10,395.13%
-
-784.14%
-2,443.03%
Earnings per share
-0.41
-0.43
-0.31
-0.41
Interest and investment income
7.10M
6.41M
5.71M
5.35M
Interest expense
-
-
-
-
Net interest expenses
7.10M
6.41M
5.71M
5.35M
Depreciation and amortization charges
-
-
-
-
EBITDA
-73.54M
-79.64M
-62.33M
-78.09M
Gain or loss from assets sale
615.00K
353.00K
35.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer